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-TEA (-tocopherol ether linked acetic acid) has been shown to induce apoptosis in 
human prostate, ovarian and breast cancer cells in culture and in xenograft models by 
promoting pro-apoptotic pathways and inhibiting anti-apoptotic pathways. Studies 
investigated the ability of -TEA to induce apoptosis in human hematological malignant 
cell lines Jurkat, Raji and U266, representing T cell leukemia, B cell lymphoma and 
multiple myeloma, respectively. The three cell lines were cultured in the presence of 
different concentrations of -TEA for different time periods, and examined for apoptosis 
 vi 
by annexin V – FITC analyses, DAPI staining, and western blotting for poly (ADP-
ribose) polymerase cleavage. -TEA induced apoptosis in all three cell lines in a dose 
and time dependent manner. Levels of pro-apoptotic molecules DR5, c-Jun N-terminal 
protein kinase (JNK), C/EBP homologous protein (CHOP), caspase 9, and caspase 3 
were upregulated in -TEA treated cells in comparison to vehicle controls. Caspase 8 
was activated in Jurkat and U266 cells but not in Raji cells. Apoptosis and pro-death 
signaling mediators were blocked by ceramide inhibitor, desipramine. The anti-apoptotic 
nuclear factor kappa B (NF-B) signaling pathway was down-regulated in -TEA treated 
Raji and U266 cells. Combinations of omega-3 fatty acid docosahexaenoic (DHA) and -
TEA significantly enhanced apoptosis in Jurkat cells in comparison to single treatments 
and vehicle control. In summary, -TEA induced apoptosis in the malignant 
hematological cell lines is via shared and distinct pathways. ASMase/ceramide-mediated 
JNK activation and endoplasmic reticulum (ER) stress mitochondrial dependent 
apoptosis are involved in -TEA induced apoptosis in the three cell lines; however, the 
cell lines exhibit cell type-specific responses to -TEA: activation of death 
receptor/caspase 8 pathway is involved in Jurkat cells, suppression of NF-B signaling is 
involved in Raji cells, and the U266 cells share both of these pathways for the induction 
of apoptosis.   

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Chapter 1: Introduction 
Vitamin E refers to a group of eight structurally distinct forms divided into 
tocopherols (and tocotrienols (tocotrienols (Gropper et al., 2004). 
The tocopherol -form is membrane associated and exhibits antioxidant properties 
(Gropper et al., 2004). Epidemiological, cell culture, and preclinical studies show that 
tocopherols, other than the  form, and tocotrienols exhibit anticancer properties 
(Constantinou et al., 2008).  Finding that the anticancer effects of vitamin E forms are 
disassociated with their antioxidant effects suggests that the structure of these compounds 
may be accountable for their anticancer effects. Based on this thought, to develop more 
potent anticancer agents, researchers have modified the structure of vitamin E forms and 
synthesized vitamin E analogs. Two examples of analogs of -Tocopherol which possess 
anticancer properties are described: vitamin E -tocopheryl succinate (VES) is 
synthesized by adding a succinate moiety to carbon 6 on the chroman head of -
tocopherol by an ester linage. VES possesses anti-proliferative activity in epithelial 
cancers such as breast cancer and colon cancer, and has no toxic effects in normal cells 
(Kline et al., 2004). However, in the body VES is hydrolyzed by cellular esterases into -
tocopherol and succinate, both of which have no detectable anticancer effects (Weber et 
al., 2002). To explore a more clinical relevant vitamin E analog for cancer treatment, our 
laboratory synthesized the RRR--tocopherol ether linked acetic acid (alpha-TEA), by 
attaching an acetic acid moiety to the chromanol head of -tocopherol molecule by a 
nonhydrolyzable ether linage (Lawson et al., 2003). Both in vitro and in vivo studies have 
shown that -TEA has selective antitumor effects in a variety of cancers (Kline et al., 
2004; Jia  et al., 2008). -TEA induces apoptosis in cancer cells but not in normal 
epithelial cells (Lawson et al., 2003). 
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Studies in our lab have shown that -TEA induced apoptosis in human breast, 
ovarian and prostate cancer cells (Snyder et al., 2008; Anderson et al., 2004; Jia et al., 
2008). The mechanisms by which these apoptotic effects are mediated involve 
upregulation of proapoptotic gene expression and donnregulation of antiapoptotic gene 
expression (Yu et al., 2010; Jia et al., 2008; Yu et al., 2006). The anticancer effects of -
TEA in hematological malignant cells have not previously been investigated.  
Docosahexaenoic acid (DHA, C22:6n-3) is a type of omega 3 (n-3) 
polyunsaturated fatty acids. Epidemiological and in vitro studies have shown that DHA 
has anticancer effects in a wide range of cancers,  including breast cancer (Jude et al., 
2006), colon cancer (Chapkin et al., 2008), prostate cancer (Shaikh et al., 2008), 
melanoma (Albino et al., 2000) and leukemia (Siddiqui et al., 2001). The anticancer 
effects of DHA have been shown to be mediated by apoptosis and cell cycle arrest 
(Shaikh et al., 2008; Siddiqui et al., 2003).  
Hematological malignancies include a large group of heterogeneous neoplasms 
originating from bone marrow or lymphatic tissue (Rodriguez-Abreu et al., 2007). These 
diseases can be broadly divided to leukemia, lymphoma and myeloma (Rodriguez-Abreu 
et al., 2007). According to SEER statistics, from 2003-2007, the age-adjusted incidence 
rates for leukemia, lymphoma and myeloma are 12.3, 22.4, and 5.6 per 100,000 men and 
women per year, respectively (Altekruse et al., 2010). The age-adjusted death rates are 
7.2, 7.3, and 5.6 per 100,000 men and women per year, for leukemia, lymphoma and 
myeloma, respectively (Altekruse et al., 2010). Among leukemia cases diagnosed from 
2003-2007, about 10.9% were under age 20. For lymphoma, only 3% were diagnosed 
under age 20 and none of myeloma cases were diagnosed under age 20 (Altekruse et al., 
2010). Although survival outcomes from hematological malignancies have improved 
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during the past decades due to early detection and improved treatments, cancer relapse 
remains a problem. Patients with certain types of leukemia, non-Hodgkin’s lymphoma or 
multiple myeloma eventually relapse and the prognosis is poor. Therefore, novel agents 
with potent anticancer properties and reduced or no toxicity are needed. Although the 
anticancer effects of -TEA have been intensively examined in human epithelial cancers, 
until now, this promising anti-cancer agent has not been investigated in human 
hematological cancers. 
In this study, (i) -TEA was shown to induce cell death by apoptosis in human 
Jurkat (T cell leukemia), Raji (B cell lymphoma), and U266 (multiple myeloma) cell 
lines. (ii) -TEA induced apoptosis in the three cell lines via common and distinct pro-
death and anti-apoptotic signaling mediators. (iii) -TEA in combination with DHA 
significantly induced apoptosis in the Jurkat cell line in comparison to single treatments 










Chapter 2: Literature Review 
VITAMIN E 
Vitamin E is a group of eight fat-soluble forms called tocopherols and tocotrienols 
that are richly contained in plant oils such as wheat germ oil, sunflower, and safflower 
(Eitenmiller, 1997; Murphy et al., 1990). Each of the eight forms is composed of a 
phenolic functional group on a chroman ring and a phytyl tail. Tocopherols and 
tocotrienols are distinguished based on whether the phytyl tail is saturated or unsaturated, 
respectively. Tocopherols and tocotrienols are classified as determined by the 
different number and position of methyl groups on the chromanol ring (Figure 1) 
(Gropper et al., 2004).  RRR--tocopherol is the most abundant form in the human body, 
and -tocopherol is the most abundant form in the American diet (Burton et al., 1998; 
Jiang et al., 2001). In the human body, RRR--tocopherol is mostly found in adipose 
tissue; whereas, it is localized to membranes in cells (Gropper et al., 2004).  
The best known physiological function of RRR--tocopherol is to maintain 
plasma membrane integrity by preventing oxidation (Gropper et al., 2004). The hydroxyl 
group on carbon 6 on the chromane ring of RRR--tocopherol denotes the hydrogen 
needed to reduce oxidized molecules, such as polyunsaturated fatty acids (Gropper et al., 
2004). Clinical studies show RRR--tocopherol to reduce the risk of cardiovascular 
disease by preventing oxidation of low density lipoproteins which contribute to the 
accumulation of lipids and macrophages on the blood vessel walls (Jialal et al., 1992; 
Mosca et al., 1997). Other functions of different vitamin E forms include suppression of 




Figure 1. Structures of vitamin E compounds. (Source: Nesaretnam, 2008) 
 
The tumor suppression effects of tocopherols and tocotrienols 
Epidemiological studies have shown that some forms of tocopherols and 
tocotrienols have protective effects against prostate cancer, colon cancer and rectal cancer 
by preventing the occurrence of cancers and suppressing tumor promotion (Wright et al., 
2007; Weinstein et al., 2005; Kune and Watson, 2006). The anticancer abilities of 
tocopherols and tocotrienols differ. Tocotrienols have stronger anticancer activity than 
tocopherols (Constantinou et al., 2008). Within the same form of vitamin E, - and - 
forms have stronger anticancer ability than - and - forms (Constantinou et al., 2008). 
Although -tocopherol has the greatest antioxidant activity among vitamin E forms, its 
anticancer property is the least. This fact suggests that the antioxidant ability and 
anticancer activity of vitamin E forms are not associated, and the minor difference in 
structure between vitamin E forms may be accountable for the different anticancer effects 
of these compounds (Constantinou et al., 2008).  
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Vitamin E Derivatives 
The structure of RRR--tocopherol has been modified in an effort to pursue more 
potent anticancer agents. One example is vitamin E -tocopheryl succinate (VES), which 
is synthesized by adding a succinate moiety to carbon 6 on the chroman head of RRR--
tocopherol by an ester linage (Figure 2) (Prasad et al., 2003). VES suppresses cell 
proliferation and induces apoptosis in a variety cancers (Neuzil et al., 1999; Yu et al., 
2002; Yu et al., 2003); however, a major  disadvantage of VES is that when administered 
in vivo the ester linkage is hydrolyzed by esterases in the body, releasing -tocohperol 
and succinate,  neither has anticancer effects (Weber et al., 2002).  
To explore a more clinical relevant vitamin E analog in cancer treatment, our 
laboratory synthesized the RRR--tocoperol ether linked acetic acid analog (alpha-TEA), 
by attaching an acetic acid moiety to carbon 6 on the chroman head of RRR--tocopherol 
by a nonhydrolyzable ether linage (Figure 2) (Lawson et al., 2003). Both in vitro and in 
vivo studies have shown that -TEA has selective antitumor effects in a variety of 
cancers (Kline et al., 2004; Jia  et al., 2008).  In vitro studies have shown that -TEA 
induces apoptosis in a variety of human epithelial tumors (breast, prostate, ovary, colon 
and lung cancers) and lymphoblastic malignancies (leukemia and lymphoma) (Lawson et 
al., 2003). Pre-clinical animal studies have shown that -TEA reduces tumor burden and 
metastasis in mouse xenograft tumor models (Lawson et al., 2003; Lawson et al., 2004; 
Zhang et al., 2004; Jia  et al., 2008; Anderson et al., 2004; Riedel et al., 2008). Compared 
to VES, -TEA shows more potent anticancer activity, probably due to the 
nonhydrolyzable ether linkage that attaches the acetic acid moiety to the chroman head 
(Lawson et al., 2004; Anderson et al., 2004).  Equally important, -TEA shows no 
detectable cytotoxic effect in normal epithelial cells and tissues (Lawson et al., 2003). 
These properties of -TEA make this compound a promising anticancer agent. 
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The mechanisms of the anticancer effects of -TEA have been explored in human 
breast, prostate and ovary cancer cells, which include enhancing pro-apoptotic cellular 
pathways and suppressing anti-apoptotic pathways. -TEA upregulates protein levels of 
death receptors Fas and DR5 and induces activation of caspase 8, 9 and 3 (Yu et al., 
2006; Jia et al., 2008; Yu et al., 2010). -TEA also induced phosphorylation of c-Jun N-
terminal kinase (JNK) which may induce apoptosis through mitochondria or via 
endoplasmic reticulum (ER) stress (Yu et al., 2006, Jia et al., 2008; Tiwary et al., 2010). 
-TEA suppresses pro-survival signaling mediators such as PI3K/AKT, Ras and ERK, 
and downregulates protein levels of anti-apoptotic factors caspase 8 homologue FLICE-
inhibitory protein (cFLIP), survivin and Bcl-2 (Jia  et al., 2008; Yu et al., 2006; Snyder et 





Figure 2. Comparison in structures between -tocopherol, VES and -TEA. 
(Source: Lawson et al., 2003) 
APOPTOSIS 
Apoptosis, also known as programmed cell death, is a form of cell death that 
differs from necrosis. Compared with necrosis, the process of apoptosis is strictly 
controlled and does not cause inflammatory reactions that could damage surrounding 
cells. Apoptosis was initially characterized by its morphological changes which involve 
condensation of nucleus and cytoplasm, fragmentation of nucleus and formation of 
apoptotic bodies (Kerr et al., 1972).  
Apoptosis has important physiological significance. It is a mechanism for normal 
development, elimination of abnormal cells and maintenance of tissue homeostasis.   
Apoptosis is executed by a class of cysteine aspartyl-specific proteases, known as 
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caspases (Nicholson 1999). In response to certain intracellular or extracellular stimuli, 
initiation caspases are cleaved and activated. Activated caspases further cleave each other 
to amplify the death signaling. Finally the executioner caspases are activated and cleave 
cellular substrate, such as proteins and chromosomes (Creagh et al., 2003). Apoptotic 
cells are typically removed by phagocytes (Kerr et al., 1972). The membrane 
phospholipid phosphatidylserine that is normally located on the inner side of cell 
membrane is exposed on the surface of cell membranes and functions as a recognition 
signal by phagocytes (Fadok et al., 1992).   
Pathways Mediating Apoptosis 
It is well known that apoptosis can be induced through two pathways: extrinsic 
pathway and intrinsic pathway (Taylor et al., 2008). In the extrinsic pathway, the ligation 
of death receptors on the cell membrane triggers trimerization of death receptors and 
recruitment of the adapter protein Fas-associated death domain protein (FADD) and 
caspase 8, forming the death-inducing signaling complex (DISC). Caspase 8 is thereby 
cleaved and activated, which in turn activates a series of downstream caspases including 
the direct apoptosis executioner caspase 3, leading to apoptosis. The intrinsic apoptosis 
pathway is dependent on mitochondria. Apoptotic signaling inside the cell triggers loss of 
mitochondria transmembrane potential, causing release of cytochrome c from 
mitochondria intermembrane. Cytochrome c together with apoptotic protease activating 
factor-1 (APAF1) and caspase 9 forms a complex called apoptosome. Activated caspase 
9 activates downstream caspases including caspase 3 which triggers apoptosis. There is 
cross talk between the extrinsic and intrinsic apoptotic pathways. Activated caspase 8 can 
cleave and activate Bid which translocates to mitochondria and activates mitochondria 
dependent apoptosis (Taylor et al., 2008). 
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Regulation of Apoptosis 
Apoptosis is strictly controlled by multiple regulatory factors. A key regulation 
factor of apoptosis is p53. The p53 protein functions as a transcription factor. Under 
normal conditions, p53 expression is kept low. In response to stress, p53 expression is 
elevated and thereby induces apoptosis by upregulating the expression of pro-apoptotic 
genes such as Fas (Müller et al., 1998), DR5 (Wu et al., 1997), BAX (Miyashita, Reed, 
1995), PUMA (Nakano, Vousden, 2001), and NOXA (Oda et al., 2000). Apoptosis is 
inhibited by Bcl-2 family proteins. Bcl-2 family proteins include anti-apoptotic proteins 
Bcl-2, Bcl-XL and pro-apoptotic proteins (BAX, Bak, Bid, Bad, Bim, NOXA, PUMA) 
(Igney, Krammer, 2002). These proteins control the integrity of mitochondria membrane. 
Activated BAX and Bak induce mitochondrial membrane transition leading to release of 
cytochrome c (Igney, Krammer, 2002). Bcl-2 and Bcl-XL inhibit activation of BAX and 
Bak (Igney, Krammer, 2002). Other regulators of apoptosis are the inhibitors of apoptosis 
(IAP) family proteins: XIAP, cIAP1, cIAP2, NAIP, ML-IAP, ILP2, KIAP, apollon and 
survivin (Deveraux, Reed, 1999). These proteins act as caspase inhibitors by mediating 
caspases degradation (Deveraux, Reed, 1999). Moreover, cFLIP is an inhibitor of caspase 
8. cFLIP has similar structure as caspase 8, but missing the catalytic site, so that it 
competes with caspase 8 to bind to DISC and prevent activation of caspase 8 (Krueger et 
al., 2001). 
CERAMIDE AND APOPTOSIS 
Ceramide is a sphingolipid that acts as a lipid second messenger (Kolesnick, 
2002). Ceramide plays an important role in the induction of apoptosis and is therefore 
called tumor suppressor lipid (Hannun, 1997). Ceramide can be produced by de novo 
synthesis, hydrolysis of sphingomyelin by the enzyme sphingomyelinase (SMase) or 
salvage pathway (Jenkins et al., 2009). There are three types of sphingomyelinase, acid 
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(aSMase), neutral (nSMase) and alkaline sphingomyelinase depending on the optimum 
pH conditions for the enzymes to work. Ceramide may be located in the caveolae or rafts 
in plasma membrane, lysosomes, mitochondria or endoplasmic reticulum (Mimeault, 
2002). 
Ceramide triggers apoptosis in response to various stresses such as 
transmembrane receptor ligation, UV radiation and chemical stress (Chen et al., 2008) . It 
has been suggested that ceramide may induce apoptosis via multiple mechanisms, 
including directly acting on mitochondria (Taha et al., 2006).  Published data show that 
ceramide increases permeability of both inner and outer mitochondria membrane, 
promoting release of cytochrome c from mitochondria (Siskind et al., 2002; Novgorodov 
et al., 2005). Plasma membrane ceramide may trigger apoptosis by inducing Fas 
oligomerization, raft coalescence and caspase 8 activation (Mimeault, 2002). In addition, 
ceramide may mediate apoptosis by signaling transduction (Taha et al., 2006).  Moreover, 
ceramide is thought to induce caspase-independent apoptosis (Taha et al., 2006).    
ENDOPLASMIC RETICULUM STRESS AND APOPTOSIS 
Endoplasmic reticulum (ER) is a subcellular organelle that is responsible for 
manipulating and transporting secretory proteins, and is also a site of Ca
2+
 storage in the 
cell (Hussain, Ramaiah, 2007). ER stress occurs when unfolded proteins accumulate in 
the ER (Xu et al., 2005). Stimuli that can induce ER stress include glucose deprivation, 
viral infection and conditions disrupting protein degradation (Xu et al., 2005). ER stress 
initially activates adaptive mechanisms to restore ER to normal status by promoting 
protein degradation and reducing protein accumulation in ER. Prolonged or excessive ER 
stress, however, induces apoptosis (Xu et al., 2005).  
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ER stress induces apoptosis via numerous mechanisms (Kim et al., 2008). One 
mechanism is through JNK-mitochondria by Ask1 (Kim et al., 2008). In ER stress, Ask1 
is activated by Ire1, causing activation of JNK. Activated JNK mediates mitochondria-
dependent apoptosis by activating the proapoptotic protein Bim and inhibiting the 
antiapoptotic protein Bcl-2 (Putcha et al., 2003; Yamamoto et al., 1999). Another 
mechanism is through inducing expression of transcription factor C/EBP homologous 
protein (CHOP). CHOP expression is induced in ER stress by ATF4, ATF6, or XBP-1 
(Kim et al., 2008). Elevated CHOP may induce apoptosis by inhibiting expression of Bcl-
2 or inducing expression of DR5 (McCullough et al., 2001; Yamaguchi, Wang, 2004). 
Moreover, Ca
2+
 released from ER during ER stress plays a critical role in apoptosis 
induction by multiple mechanisms (Breckenridge et al., 2003). Ca
2+
 can directly increase 
mitochondria permeability by flowing into mitochondria (Kroemer, Reed, 2000). Ca
2+
 
released from ER also activates Ca
2+ 
dependent proteases calpain which activates Bax 
and Bid and inhibiting Bcl-2 and Bcl-XL by direct cleavage (Rizzuto et al., 2003; 
Breckenridge et al., 2003). 
APOPTOSIS AND CANCER 
Resistance to apoptosis is a hallmark of cancer (Hanahan, Weinberg, 2000). The 
mechanisms of apoptosis resistance in cancer cells involve increased anti-apoptotic 
signaling and decreased pro-apoptotic signaling (Igney, Krammer, 2002). Aberrant 
elevated PI3K/AKT and constitutively activated NF-B signaling are often found in 
tumor cells (Igney, Krammer, 2002). In addition, anti-apoptotic molecules such as Bcl-2, 
Bcl-XL, IAP proteins, and cFLIP are often overexpressed in tumor cells (Igney, 
Krammer, 2002). On the other hand, pro-apoptotic signaling is attenuated in tumors. For 
example, the central apoptosis regulator p53 gene is mutated or deleted in half numbers 
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of tumors (Harris, 1996). Moreover, malfunction of death receptors is also found in some 
tumors (Igney, Krammer, 2002). Novel molecular treatments that target these altered 
signaling mediators are under intense investigation and are promising cancer therapeutic 
strategies (Nicholson, 2000).  
HEMATOLOGICAL MALIGNANCIES 
Hematological malignancies are neoplasm happened in lymphatic system or bone 
marrow. These diseases can be roughly classified as leukemia, lymphoma and plasma cell 
neoplasms (Rodriguez-Abreu et al., 2007). The estimated new cases of hematopoietic 
malignancies in the United States in 2009 are 139,860, accounting for about 9% of all 
newly diagnosed cancers, and the estimated deaths from these cancers are 53,240 
(American Cancer Society, 2009). 
Leukemia 
Leukemia originates from blood and bone marrow. Leukemia can be divided to 
four major types: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), 
chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Leukemia is 
the most common cancer in children aged from 0 to 14, accounting for 32.7% of all 
childhood cancers and causing about one third of cancer-related deaths in children 
(American Cancer Society, 2009). However, leukemia is found more often in adults than 
in children. According to SEER report, from 2003 to 2007, the median age at leukemia 
diagnosis is 66 years old (Altekruse et al., 2010). Although the outcome of leukemia in 
children is good with survival rate about 80-85%, the outcome in adult leukemia patients 
is poor and leukemia in most patients will relapse (Larson, Stock, 2008). The 3 year 
survival rate for adult ALL is only 30-40% (Rowe et al., 2005). 
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For acute leukemia, patients usually are given chemotherapy followed by 
consolidation chemotherapy or autologous/allogeneic stem cell transplantation depending 
on age and prognostic factors of patients (Shipley, Butera, 2009). Immunological therapy 
is a relatively new strategy that is under intense development (Shipley, Butera, 2009). For 
chronic leukemia, treatments are usually given in advanced diseases. For early stage 
diseases, treatment is given only when disease progresses, otherwise a “watch and wait” 
monitoring strategy is applied (Hallek et al., 2005). 
New agents targeting specific genetic alterations in tumor cells have been 
developed, including multidrug resistance inhibitors, proteosome inhibitors, 
antiangiogenesis agents, tyrosine kinase inhibitors, and apoptosis inhibitors (Tallman, 
2005).  Such agents hold promise for improvement of outcome in patients with poor 
prognostic factors, older patients who cannot tolerate intense chemotherapy, and 
relapsed/refractory cases. 
Lymphoma 
Lymphomas are neoplasms originating from immune systems including both 
lymphoid tissues and extranodal organs. According to the pathological characteristics 
lymphoma can be divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma 
(NHL). The majority of lymphoma cases are NHL, accounting for 88.6% of lymphoma 
new cases in 2009 (American Cancer Society, 2009). The Hodgkin’s lymphoma is 
identified by the presence of Reed-Sternberg cells (Mastasar, Zelenetz, 2008). Treatments 
of early stage lymphoma include radiotherapy, chemotherapy, or combined radiotherapy 
and chemotherapy. Intensive chemotherapy and autologous or allogeneic stem cell 
transplantation are used for relapsed or refractory patients (Mastasar, Zelenetz, 2008). 
Immunotherapy is under active development for the treatment of lymphoma. The most 
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intensively studied immunotherapeutic agent is rituximab, a monoclonal antibody against 
the general B cell marker CD20, which may be used alone or in combination with 
chemotherapy or stem cell transplantation (Mawardi et al., 2009). Clinical studies have 
shown that rituximab improve survival rates in relapsed and refractory patients (Van 
Oers, et al., 2006). Classical HL is considered a curable disease. Most HL patients treated 
with radiotherapy or combined radiotherapy and chemotherapy have very good outcome 
with a 5 year relative survival rate of 86.8% for cases diagnosed in 1999-2006 (Altekruse, 
2010). Compared to HL, NHL has relatively poor outcome with 5 year relative rate of 
69.1% in 1999-2006 (Altekruse, 2010).  
Anti-apoptotic molecules including cFLIP and XIAP have been found to be 
responsible for apoptosis resistance and pathogenesis of HL (Evens, et al., 2008), making 
these genes targets of potential therapeutic strategies.  
Myeloma 
Multiple myeloma (MM) is a B cell (antibody secreting plasma cell) malignancy 
characterized by accumulation of malignant plasma cells in the bone marrow. MM is the 
second most common hematological malignancy after non-Hodgkin lymphoma in the 
United States (Raab et al., 2009). Estimated new cases and deaths in 2009 in the United 
States are 20,580 and 10,580, respectively (American Cancer Society, 2009).  MM is 
more common in African Americans than in whites. Traditional therapy for this disease is 
chemotherapy followed by stem cell transplantation for patients younger than 65 or 
continuous chemotherapy for those not eligible for stem cell transplantation (Kyle, 
Rajkumar, 2008). Patients usually have a short time remission followed by relapse 
(Schwartz, Vozniak, 2008). With intense drug development during the past several years, 
novel agents are now being used in the clinic, i.e., Bortezomib, Thalidomide and 
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Lenalidomide (Laubach et al., 2009). Because of these advances, the outcome of multiple 
myeloma has improved. However, multiple myeloma is still an incurable disease and the 
five year survival rate is only around 34% (Brenner et al., 2008). Moreover, side effects 
of current therapeutic agents remain a problem.  
CANCER CELL LINES 
Three cell lines were used in this study: Jurkat, Raji and U266. The Jurkat cell 
line is derived from the peripheral blood of a 14-year-old male patient with T-lineage 
ALL (Schneider et al., 1977).  The Raji cell line is derived from an 11-year-old male 
patient with Burkitt’s lymphoma, a B cell origin non-Hodgkin’s lymphoma, in 1963 
(Pulvertaft, 1964). The U266 cell line is derived from the peripheral blood of a 53-year-
old male patient with multiple myeloma (Nilsson et al., 1970). U266 cells produce 













Chapter 3: Materials and Methods 
CHEMICALS AND REAGENTS 
-TEA was prepared as previously described (Lawson et al., 2003). A 40 M 
stock solution was made by dissolving -TEA in ethanol. DHA and desipramine were 
purchased from Sigma-Aldrich (St. Louis, MO). A 100 mM stock solution of DHA was 
made with DMSO and stored. A 50 mM stock solution of desipramine was solubilized 
with DMSO and stored. All stock solutions were stored at -20°C. Chemicals were diluted 
with medium before treatment. 
Primary antibodies used for western blotting include: PARP (Santa Cruz), caspase 
8 (Cell Signaling), caspase 9 (Cell Signaling), caspase 3 (Santa Cruz), Bid (BD 
Pharmingen), Fas (Santa Cruz), DR5(Cell Signaling), p-JNK(Cell Signaling), JNK(Santa 
Cruz), p-cJun(Santa Cruz), CHOP (Santa Cruz), p-IB (Cell Signaling), IB (Santa 
Cruz), cyclinD1 (Santa Cruz), XIAP (Cell Signaling), cFLIP (Santa Cruz), survivin 
(Santa Cruz), Bcl-2 (Santa Cruz), and GAPDH (Cell Signaling).  
CELL CULTURE 
Human acute lymphoblastic leukemia cell line Jurkat, and Human Burkitt’s 
lymphoma cell line Raji, available in our lab, were cultured in RPMI 1640 medium 
(GIBCO), supplemented with 10% fetal bovine serum (FBS) (GIBCO), 200 mM 
glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (GIBCO), and 4.5 g/L glucose 
(Sigma). Human myeloma cell line U266 was purchased from ATCC, Manassas, VA. 
U266 cells were cultured in RPMI 1640 medium supplemented with 15% FBS, 200 mM 
glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Cells were maintained in 
37°C incubator with humidity and 5% CO2. Cells were plated at a density of 5 × 10
5
 
cells/ml in 2% FBS supplemented medium before treatment. 
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DAPI STAINING FOR APOPTOSIS EVALUATION 
Apoptosis was evaluated by staining the nucleus with 4’, 6’-diamidino-2-
phenylindole (DAPI). DAPI strongly binds to nucleic acid in live and dead cells, 
allowing observation of nuclear morphological change during apoptosis. DAPI (Roche 
Diagnostics, Indianapolis, IN) was diluted with methanol. Treated cells were collected, 
washed with PBS, and incubated with DAPI solution (5 g/ml) in methanol at 37°C for 5 
minutes. Cells were then observed under a fluorescent microscope (Olympus IX71). Cells 
containing condensed or fragmented nuclei were counted as apoptotic cells. For each 
sample, at least 300 cells were counted. Data were expressed as percentage of apoptotic 
cells to total counted cells. 
ANNEXIN V- FITC FLOW CYTOMETRY ANALYSIS 
Apoptosis was also evaluated by annexin V-FITC/propidium iodide (PI) flow 
cytometry analysis. The protein annexin V binds to phosphatidylserine which is 
externalized of plasma membrane during early stage of apoptosis, thus allowing detection 
of apoptotic cells by measuring the fluorescein conjugated with annexin V. PI is a dye 
which cannot penetrate plasma membrane of viable cells but can easily enter dead or late 
stage apoptotic cells to bind to DNA. Cells were plated at 5 × 10
5
 cells/ml in 2% FBS 
medium and cultured overnight. Cells were then treated with -TEA or DHA for 
different time points. Treated cells were collected, washed with ice cold PBS twice, 
resuspended in annexin V-FITC (Invitrogen, Carlsbad, CA) in binding buffer (BD 
Biosciences Parmingen, San Diego, CA) and incubated at room temperature for 15 
minutes. Right before measurement, PI (Invitrogen) solution (1:1000 diluted in PBS) was 
added. The C6 flow cytometer® (Accuri Cytometers, Inc. Ann Arbor, MI) was used to 
measure the fluorescence. CFlow® software (Accuri Cytometers, Inc. Ann Arbor, MI) 
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was used to analyze data. Data were expressed by percentage of annexin V-FITC positive 
to total cells. 
WESTERN BLOT ANALYSIS 
Treated cells were collected by centrifuge at 1400 rpm for 4 minutes and washed 
once with PBS. Cell pellets were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% 
SDS, 50 mM Tris, 0.5% deoxycholate, pH 7.4) and kept on ice for 20 minutes. Cell 
lysates were vortexed and centrifuged at 13,000 rpm for 10 minutes at 4°C. Supernatants 
containing cellular proteins were used for western blot analysis. Cellular proteins were 
quantified using Bio-Rad protein assay (Bio-Rad, Hercules, CA). 20 g protein was 
resolved by SDS-PAGE and transferred to nitrocellulose membranes (Optitran BA-S 
supported nitrocellulose). Membranes were blocked by 5% nonfat dried milk in 1 × 
TBST (20mM Tris, 150mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 
minutes, and then incubated with primary antibodies 1:1000 diluted in 0.1% BSA 
solution in TBST overnight at 4°C. Membranes were washed with TBST for 5 minutes 
and then incubated with horseradish peroxidase conjugated goat-anti-mouse or goat-anti-
rabbit secondary antibodies (Jackson Immunoresearch, Rockford, IL) 1:1000 or 1:2000 
diluted in 5% milk in TBST at room temperature for 35 minutes. After 3 times of wash 
with TBST protein bands were visualized by enhanced chemiluminescence (Perkin 
Elmer, Waltham, MA). Densitometric analysis of protein bands was performed using 
ImageJ software (http://rsbweb.nih.gov/ij). 
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION 
The XBP-1 mRNA splice variants were detected using Reverse Transcription 
PCR (RT-PCR). Treated cells were collected and washed with PBS. Total cellular RNA 
was isolated using RNeasy Mini Kit (Qiagen Inc., Valencia, CA) following 
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manufacturer’s instruction. RT-PCR was performed using SuperScript™ One-Step RT-
PCR with Platinum® Taq (Invitrogen, Carlsbad, CA). -actin mRNA levels were also 
measured as loading control. The primers used to detect XBP-1 were:  
5’-AAACAGAGTAGCAGCTCAGACTGC-3’(forward) and  
5’-TCCTTCTGGGTAGACCTCTGGGAG-3’(reverse).  
The primers used to detect -actin were: 
 5’-GGCGGCACCACCATGTACCCT-3’(forward) and  
5’-AGGGCCGGACTCGTCATACT-3’(reverse).  
PCR products were subject to DNA electrophoresis. 
STATISTICAL ANALYSIS 
Student’s t-test was performed to determine significant difference between control 











Chapter 4: Results 
-TEA INDUCED APOPTOSIS IN HUMAN HEMATOLOGICAL MALIGNANT CELLS 
The pro-apoptotic effect of -TEA in human hematological malignant cells was 
evaluated by DAPI nucleus staining. Human T cell leukemia (Jurkat), B cell lymphoma 
(Raji) and multiple myeloma (U266) cells were plated at 5 × 10
5
 cells/ml in reduced 
serum (2%) medium and allowed to grow overnight.  The three cell types were treated 
with vehicle or -TEA for 24 hours at their exponential growth phase. DAPI staining of 
cells treated with -TEA showed condensed chromatin and fragmented nuclei which is 
characteristic of apoptotic cells (Figure 3). 
-TEA induction of apoptosis in these cell types was determined by annexin V-
FITC/PI analyses. The three cell types were treated with 5, 10 and 20 M -TEA or 
vehicle for 24 hours (Fig 4A).  Jurkat cells were the most sensitive with -TEA 
significantly inducing apoptosis in Jurkat (5 M), U266 (10 M), and Raji (20 M) in 
comparison to controls (Fig 4A). Jurkat, Raji and U266 cells were treated with 10, 20 and 
10 M of -TEA, respectively, for 8, 16, and 24 hours.   Significantly enhanced levels of 
apoptosis were detected in Jurkat, Raji, and U266 cells at 16, 8, and 16 hours, 









Figure 3. Pro-apoptotic effect of -TEA in Jurkat, Raji and U266 cells as evaluated 
by DAPI nuclei staining. Jurkat, Raji and U266 cells were treated with vehicle or -
TEA 5 M (Jurkat) or 20 M (Raji and U266) for 24 hours. Cells were collected and 
stained with DAPI. Apoptosis was indicated by nuclear fragmentation and shrinkage. 





Figure 4. Pro-apoptotic effect of -TEA in Jurkat, Raji and U266 cells as evaluated 
by annexin V-FITC/PI analyses. (A) Cells were treated with vehicle or -TEA (5, 10, 
or 20 M) for 24 hours. (B) Cells were treated with vehicle or -TEA (10 or 20 M) for 
8, 16, or 24 hours. Apoptosis was evaluated by annexin V-FITC/PI analysis. Data are 
presented as mean ± SD of three independent experiments. Student’s t test was used to 
determine the statistical significance. *: P < 0.05 relative to vehiclecontrol. **: P < 0.01 






-TEA INDUCED ACTIVATION OF MOLECULES IN APOPTOTIC PATHWAYS 
Western blot analyses were conducted to determine apoptotic pathway mediators 
induced by -TEA. Jurkat, Raji and U266 cells were treated with 10, 20 or 15 M of -
TEA, respectively, or vehicle for various time periods.  Whole cell lysates were analyzed 
by western blots analysis.   Caspase 3 substrate, PARP (apoptosis indicator), was cleaved 
in all the three cell lines in response to -TEA treatment. Caspases 9 and 3 were activated 
(cleaved) in all three cell lines. Caspase 8 and Bid activation (tBid) were observed in 
Jurkat and U266 cells, but not in Raji cells. These data suggest that -TEA induced 
apoptosis in Jurkat and U266 cells is caspase 8 dependent and that Bid cleavage activates 











Figure 5. Signaling mediators involved in -TEA induced apoptosis in Jurkat, Raji 
and U266 cells. Jurkat, Raji and U266 cells were treated with vehicle or -TEA at 
indicated doses for various time periods. Whole cell lysates were analyzed for protein 
levels of cleaved PARP, caspases 8, 9, and 3, Bid and tBid by western blotting. GAPDH 







-TEA UPREGULATED DEATH RECEPTORS, PHOSPHO-JNK AND INDUCED 
ENDOPLASMIC RETICULUM  (ER) STRESS IN JURKAT, RAJI AND U266 CELLS 
To further explore the upstream signaling mediators that trigger the apoptotic 
pathways, protein levels of JNK and CHOP were examined by western blot analysis 
(Figure 6A). Jurkat, Raji and U266 cells were treated with -TEA or vehicle for various 
time periods and whole cell lysates were analysed by western blotting. Protein levels of 
death receptor DR5 were upregulated in all three cell lines; whereas, elevated Fas levels 
were observed in Jurkat and Raji cells but not in U266 cells. These data show that death 
receptors are involved in -TEA induced apoptosis in Jurkat and U266 cells. For Raji 
cells, since caspase 8 activation was not observed, the role of Fas and DR5 upregulation 
needs further identification.  Furthermore, levels of phospho-JNK2/1, cJun, and CHOP 
were upregulated in all three cell lines (Figure 6A). Splicing of XBP-1 mRNA was 
induced by -TEA (Figure 6B), further showing that ER stress is induced in response to 
-TEA treatment in the three cell lines, and that ER stress is involved in -TEA induced 
















Figure 6. -TEA upregulated death receptors, phospho-JNK and induced ER stress 
markers in Jurkat, Raji and U266 cells. Jurkat, Raji and U266 cells were treated with 
vehicle or -TEA at indicated doses for various time periods. (A) Whole cell lysates were 
prepared to detect protein levels of Fas, DR5, JNK, cJun and CHOP by western blotting. 
GAPDH was used as a loading control. Data are representative of three independent 
experiments. (B) RT-PCR was performed to examine XBP-1 mRNA splicing status. -
actin was used as a loading control. 
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-TEA INDUCED APOPTOSIS WAS INHIBITED BY ACID SPHINGOMYELINASE INHIBITOR 
DESIPRAMINE  
Previous studies suggested that the lipid second messenger ceramide plays an 
important role in inducing apoptosis. Recent work in our lab shows that ceramide is 
involved in -TEA induced apoptosis in human breast cancer cells. Ceramide is 
generated in plasma membrane from sphingomyelin hydrolysis catalyzed by acid 
sphingomyelinase (aSMase). To determine if ceramide is involved in apoptosis induction 
by -TEA in human hematological malignant cells, Jurkat, Raji and U266 cells were pre-
treated with   inhibitor of aSMase, desipramine, followed by -TEA treatment (Figures 7 
& 8).  Apoptosis induced by -TEA in Jurkat, Raji and U266 cells was inhibited by 
desipramine as indicated by reduced PARP cleavage (Figure 7A & B), and reduced 
caspase 9 in the three cell lines.  Caspase 8 and tBid were reduced in Jurkat and U266 
cells (Figure 7A). Moreover, desipramine partially blocked -TEA-induced upregulation 
of JNK2/1 and p-cJun in the three cell lines. CHOP protein levels were reduced in Jurkat 
and Raji cells (Figure 8). These data suggest that ceramide generated from sphingomyelin 
hydrolysis may function as an upstream factor that is responsible for apoptosis induction 














Figure 7. -TEA induced apoptosis was inhibited by aSMase inhibitor desipramine. 
Jurkat, Raji and U266 cells were pretreated with vehicle or desipramine  at 25 M for 2 
hours, followed by vehicle or -TEA (10 M in Jurkat, 20 M in Raji, or 15 M in 
U266) treatment for 9 hours. (A) Whole cell lysates were tested by western blotting for 
protein levels of PARP, caspase 8, caspase 9 and Bid. (B) Densitometric analysis of the 
PARP cleavage bands in western blotting. A data are representative of three independent 
experiments. B data are depicted as mean ± S.D. of three independent experiments.  * = 
significantly different from vehicle control  P < 0.05.   
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Figure 8. Desipramine partially blocked -TEA-induced upregulation of phospho-
JNK and CHOP. Jurkat, Raji and U266 cells were pretreated with vehicle or 
desipramine 25 M for 2 hours, followed by vehicle or -TEA (10 M in Jurkat, 20 M 
in Raji, or 15 M in U266) treatment for 9 hours. Whole cell lysates were tested by 
western blotting for protein levels of phospho-JNK2/1, JNK 2/1, p-cJun and CHOP.  
GAPDH served as lane load controls. Data are representative of three independent 







-TEA DOWNREGULATED ANTI-APOPTOTIC MEDIATORS IN JURKAT, RAJI AND U266 
CELLS 
To test the effects of -TEA on anti-apoptotic signaling mediators in Jurkat, Raji 
and U266 cells, the three cells were treated with vehicle or -TEA for various time 
periods, followed by western blotting of whole cell lysates for detection of anti-apoptotic 
protein levels (Figure 9). -TEA downregulated the levels of phospho-IB in Raji and 
U266 cells, but not Jurkat cells, suggesting inhibition of the NF-B signaling in Raji and 
U266 cells (Figure 9). Furthermore, antiapoptotic proteins XIAP (Raji and U266), cFLIP 
(Jurkat, Raji and U266), survivin (Raji and U266) and Bcl-2 (Raji) were downregulated 











Figure 9. -TEA downregulated anti-apoptotic factors in Jurkat, Raji and U266 
cells. Jurkat, Raji and U266 cells were treated with vehicle or -TEA at indicated doses 
for various time periods. Whole cell lysates were prepared to detect protein levels of a 
number of antiapoptotic proteins by western blotting. GAPDH was used as a loading 






THE APOPTOTIC EFFECTS OF DHA IN JURKAT AND U266 CELLS 
To explore possible cooperative effects of -TEA, the apoptotic-inducing 
properties of DHA were first tested in Jurkat and U266 cells. Jurkat and U266 cells were 
treated with DHA at 20-80 M for 24 hours. Apoptosis was evaluated by annexin V-
FITC/PI analysis (Figure 10). Data show that DHA significantly induced apoptosis in 
Jurkat and U266 cells in a dose dependent manner. Jurkat cells were more sensitive to 
DHA compared with U266 cells (Figure 10). 
 
Figure 10. The apoptotic effects of DHA in Jurkat and U266 cells. Jurkat and U266 
cells were treated with vehicle or DHA (20, 40, or 80 M) for 24 hours. Apoptosis was 
evaluated by annexin V-FITC/PI analysis. Data are presented as the mean ± S.D. of three 
independent experiments. Student’s t test was used to determine the statistical 
significance. *: P < 0.05 relative to vehicle treatment. **: P < 0.01 relative to vehicle 
treatment. 
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THE EFFECTS OF DHA ON ANTI- AND PRO-APOPTOTIC GENES IN JURKAT AND U266 
CELLS 
To further examine mediators involved in DHA induced apoptosis in Jurkat and 
U266 cells, both cell lines were treated with vehicle or DHA at various doses (Figures 11 
and 12). DHA increased levels of cleaved PARP, p-IB, p-JNK 2/1, CHOP, and DR5, 
and reduced levels of anti-apoptotic mediators survivin and Cflip in Jurkat cells (Figure 
11).    
Treatment of U266 cells with 15, 30, or 60 M DHA for 16 hours enhanced levels 
of cleaved PARP, phospho-JNK 2/1, CHOP and DR5, and reduced levels of anti-







Figure 11. The effects of DHA on pro- and anti-apoptotic molecules in Jurkat cells. 
Jurkat cells were treated with vehicle or DHA (10, 20, or 40 M) for 8 hours (left panel); 
or treated with vehicle or DHA 40 M for 3, 6, or 9 hours. Western blot analyses were 
performed to detect protein levels of several anti- and pro-apoptotic genes. Data are 
representative of three independent experiments. 
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Figure 12. The effects of DHA on pro- and anti-apoptotic molecules in U266 cells. 
U266 cells were treated with vehicle or DHA (15, 30, or 60 M) for 16 hours. Western 
blot analyses were performed to detect protein levels of several anti- and pro-apoptotic 





COMBINATION EFFECTS OF -TEA PLUS DHA IN JURKAT AND U266 CELLS 
To examine the combination effects of -TEA and DHA in human hematological 
malignant cells, Jurkat and U266 cells were treated with DHA (10 or 20 M), -TEA 
(2.5 or 5 M) alone or together for 24 hours. Apoptosis was evaluated by annexin V-
FITC/PI analysis (Figure 13). The combination of -TEA plus DHA exhibited enhanced 
apoptotic effects in Jurkat cells, but not in U266 cells (Figure 13).  The combination of -
TEA plus DHA acted cooperatively to enhance levels of cleaved PARP, p-IB, p-JNK 
2/1, CHOP and DR5, and to reduce levels of cFLIP in Jurkat cells.  Survivin levels were 















Figure 13. Combination apoptotic effects of -TEA plus DHA in Jurkat and U266 
cells. Jurkat and U266 cells were treated with DHA (10 or 20 M), -TEA (2.5 or 5 M) 
alone or together for 24 hours. Apoptosis was evaluated by annexin V- FITC/PI flow 
cytometry analysis. Results represent mean ± SD of three independent experiments. 
Student’s t test was used to determine the statistical significance. *: Significant difference 








Figure 14. Combination effects of -TEA plus DHA on anti- and pro-apoptotic 
proteins in Jurkat cells. Jurkat cells were treated with -TEA (5 M) or DHA (20 M) 
alone or in combination for 9 hours. Western blot analyses were performed to detect 
protein levels of several anti- and pro-apoptotic mediators. Data are representative of two 
independent experiments. 
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   Chapter 5: Discussion 
Studies examined the ability of vitamin E analog -TEA to induce apoptosis in 
human hematological malignant T cells (Jurkat), B cells (Raji), and multiple myeloma 
plasma cells (U266), omega-3 fatty acid DHA alone and in combination with -TEA to 
induce apoptosis in Jurkat and U266 cells. -TEA and DHA alone significantly induced 
apoptosis in the cell lines in comparison to control, and the combination of -TEA and 
DHA acted cooperatively to induce apoptosis in Jurkat cells but not U266 cells. Jurkat 
cells were the most sensitive to -TEA-induced apoptosis, and Raji cells were the least 
sensitive. Compared with human breast cancer cells, the hematological cells showed 
greater sensitivity to -TEA-induced apoptosis (Yu et al., 2010; Tiwary et al., 2010).  
The high sensitivity of hematological malignant cells to -TEA-induced apoptosis 
provides the scientific basis for using -TEA as a treatment in hematological tumors, 
especially given the fact that hematological malignant cells occur in the blood and bone 
marrow where higher concentrations of -TEA are easier to obtain.  
-TEA-induced apoptosis in hematological malignant cells was shown to be via 
extrinsic and intrinsic apoptotic pathways. -TEA induced activation of caspase 8, 9 and 
3 in Jurkat and U266 cells, and caspase 9 and 3 in Raji cells. In addition, Bid cleavage 
was induced in Jurkat and U266 cells. These data suggest that -TEA-induced apoptosis 
in Jurkat and U266 cells is via caspase 8-dependent mitochondria pathway involving 
caspase 8 activation of tBid. However, the -TEA-induced apoptosis in Raji cells is 
caspase 8-independent, involving only the intrinsic mitochondria pathway. Aspirin-
induced apoptosis in Raji cells involves caspase 8, 9 and 3 activation (Pique et al., 2000). 
Fas ligand-induced apoptosis in Raji cells involves DISC formation and caspase 8 
activation (Bando et al., 2003) On the other hand, CM1 (centrocyte/-blast marker 1) 
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induces apoptosis in Raji cells only by changing mitochondrial permeability, and 
Fas/caspase 8 is not involved (Kim et al., 2002). The fact that death receptor/caspase 8 
signaling is not involved in -TEA-induced apoptosis in Raji cells may explain why Raji 
cells are less sensitive to -TEA-induced apoptosis in comparison with Jurkat and U266 
cells. 
Studies were conducted to determine if death receptors were involved in -TEA 
induced apoptosis. -TEA upregulated protein expression of death receptors Fas (Jurkat 
and Raji) and DR5, active form of JNK and cJun, and CHOP in these cells. These data 
suggest that death receptor/caspase 8 signaling is involved in -TEA-induced apoptosis 
in Jurkat and U266 cells. Whereas, in Raji cells, death receptors may not be involved 
since data show that caspase 8 is not activated in these cells. JNK activation appears to 
have a role in the apoptosis in all the three cell lines. Studies also showed that ER stress 
was involved in -TEA induction of apoptosis. ER stress marker CHOP was upregulated, 
and XBP-1 mRNA splicing was induced by -TEA in all three lines, suggesting ER 
stress involvement. ER stress may mediate the apoptotic effect by activating JNK which 
in turn induce mitochondria-dependent apoptosis; or by increasing CHOP expression 
which induces DR5 expression (Kim et al., 2008; Yamaguchi, Wang, 2004). 
To examine the possible involvement of ceramide in apoptosis induction by -
TEA, the aSMase inhibitor desipramine (inhibits ceramide formation) was used to 
pretreat these cells prior to -TEA treatment. Desipramine partially blocked -TEA-
induced apoptosis in the three cell lines as indicated by reduced PARP cleavage. In 
addition, desipramine inhibited activation of caspases and Bid, as well as upregulation of 
proapoptotic molecules JNK and CHOP (Jurkat and Raji). These data suggest that 
ceramide generated from sphingomyelin hydrolysis by aSMase functions as an upstream 
apoptosis mediator in -TEA-induced cell death. It has been reported that JNK plays a 
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critical role in ceramide induced apoptosis (Chen et al., 2008). Ceramide induces JNK 
phosphorylation, phospho-JNK activates Bim and induces apoptosis via the 
mitochondria-dependent pathway (Chen et al., 2008). Ceramide has also been reported to 
act upstream of ER stress to induce apoptosis (Sauane et al., 2010; Chen et al., 2008). 
This may explain the data showing reduced levels of CHOP in Jurkat and Raji cells 
pretreated with desipramine. This effect was not seen in U266 cells, suggesting de novo 
synthesis of ceramide may play a bigger role in U266 cells, or the interaction between 
ceramide and ER is cell specific. The inhibitory effects of desipramine on JNK activation 
and CHOP expression were not equivalent. While JNK activation was almost totally 
abolished by desipramine in Jurkat and Raji cells, elevated CHOP expression in these 
cells was only inhibited to a much less level. The same trend also happened in U266 cell, 
where JNK activation was inhibited while CHOP expression was not affected by 
desipramine. These results suggest that JNK activation in these cells in response to -
TEA is independent of ER stress. 
In addition to the effects on proapoptotic genes, -TEA also downregulated levels 
of antiapoptotic molecules cFLIP, survivin, Bcl-2, and XIAP. These alterations were 
correlated with downregulation of phospho-IB in Raji and U266 cells, suggesting NF-
kB involvement. It has been reported that NF-B signaling is constitutively activated in 
Raji and U266 cells, and inhibiting this signaling is sufficient to induce apoptosis (Malara 
et al., 2008; Zhang et al., 2008).  
In exploring possible combination applications of -TEA, DHA was tested 
separately and in combination with -TEA in Jurkat and U266 cells. DHA induced 
apoptosis in Jurkat and U266 cells at 40 M, which is lower than the physiologically 
relevant dose of DHA, 50 M (Kim et al., 2010). Data also showed that the combination 
of -TEA plus DHA acted cooperatively in induction of apoptosis in Jurkat cells, but not 
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in U266 cells. This enhanced apoptotic effect  in Jurkat cells was correlated with 
enhanced upregulation of pro-apoptotic mediators DR5, phospho-JNK and CHOP, and 
downregulation of anti-apoptotic mediators cFLIP and survivin. Interestingly, phospho-
IB in Jurkat cells was upregulated by -TEA and DHA when tested alone, and this 
effect was enhanced with the combination treatment. Although NF-B signaling is 
implicated in elevated proliferation and apoptosis resistance in many cancer cells, it also 
exhibits proapoptotic effects probably by inducing transcription of proapoptotic genes 
such as Fas and Fas ligand (Collett, Campbell, 2006). Another proposed mechanism for 
NF-B to induce apoptosis is through specific inhibition of CDK4 activity which induces 
translocation of RelA from cytoplasm to nucleoplasm and then to nucleolus (Thoms et 
al., 2007). In addition, NF-B is reported to mediate UV-induced apoptosis by promoting 
JNK activation (Liu et al., 2006). The role of NF-B signaling in Jurkat cells in response 


















Chapter 6: Summary and Future Studies 
In summary, human hematological malignant Jurkat (T-lineage leukemia), Raji 
(B-lineage lymphoma) and U266 (multiple myeloma) cells exhibited high sensitivity to 
-TEA induced apoptosis. There were common mechanisms mediating the apoptotic 
effects of -TEA in the three cell lines, as well as cell type-specific mediators. Ceramide 
generated from sphingomyelin hydrolysis by aSMase appears to play an upstream role in 
the events involved in -TEA-induced apoptosis in the three cell lines. Based on these 
studies, we propose that ceramide, as an upstream mediator, enhances -TEA-induced 
apoptosis by activating JNK and ER stress. We propose that activated JNK involvement 
in -TEA induced apoptosis is via activation Bim which translocates to mitochondria, 
triggering mitochondrial permeability transition. ER stress induces death receptor-
dependent and mitochondria/caspase-dependent apoptotic pathways. Death 
receptor/caspase 8 signaling is involved in -TEA induced apoptosis in Jurkat and U266 
cells, but not in Raji cells.  -TEA down-regulation of anti-apoptotic genes XIAP, cFLIP 
and survivin enhances apoptosis by removing inhibitors of death receptor signaling. The 
relationship between ceramide generation and downregulation of these anti-apoptotic 
mediators require further study. Enhanced apoptotic actions of the combination of -TEA 
plus DHA provide a potential new treatment for T lineage based leukemia.    
Future studies include: 
1. Further confirmation of the involvement of ER stress, death receptors, and 
JNK in -TEA-induced apoptosis by conducting knock down studies 
using siRNA and chemical inhibitors. 
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2. Further examination of the involvement of NF-B signaling pathway in -
TEA-induced apoptosis by conducting knock down and over-expression 
studies. 
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